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l Liquid ventilation with perfluorocarbon (PFCV) has advan- 
tages over conventional gas ventilation (GV) in premature 
and lung-injured newborn animals. Indirect calorimetric mea- 
surement of both oxygen consumption (\iO,) and carbon 
dioxide production (\iCO,) during PFCV has not been previ- 
ously performed. In addition, comparison to indirect calori- 
metric measurement of \iO, and \jCOz during GV has not 
been evaluated. Ten fasted normal cats weighing 2.6 to 3.9 kg 
were anesthetized with pentobarbital and pancuronium. 
Tracheostomy was performed. Gas exchange was measured 
across the native lung during GV and across the membrane 
lung of the liquid ventilator during PFCV. \j02 was measured 
using a modification of a previously described, indirect, 
closed-circuit, volumetric technique. \jCOz was analyzed by 
capnographic assay of the mixed-expired closed-circuit air. 
The \iCOJ\iO 2 ratio (RQ) was calculated. There was no 
change in VO,, \jCOz, or RCI during PFCV when compared 
with GV (\j02: GV = 5.7 ,f 0.3 mL/ kg/min, PFCV = 5.6 2 0.5 
mL/kg/min [P = NS]; VC02 : GV = 4.9 + 1.1 mL/kg/min, 
PFCV = 4.8 2 0.9 mL/kg/min [P = NS]; RO: GV = 
0.85 * 0.21, PFCV = 0.86 f 0.21 [P = NS]). During GV the 
Pa02 was higher than during PFCV (PaOt: GV = 335 & 70 
mm Hg, PFCV = 267 i 83 mm Hg [P = .04]). as is expected 
because of the relative reduction in the inspiratory Pi02 of the 
perfluorocarbon during liquid ventilation. There was no 
significant change in the PaC02 (PaC02: GV = 37.3 + 2.2 mm 
Hg, PFCV = 40.4 2 5.3 mm Hg [P = NS] or the pH (pH: 
GV = 7.34 r 0.04, PFCV = 7.35 -c 0.06 [p = NS]): This study 
demonstrates the efficacy of measuring VOz and VCO2 during 
gas and liquid ventilation using an indirect calorimetric 
technique. The data demonstrate that V02 and \jCOz do not 
change during liquid ventilation and that excellent gas ex- 
change can be accomplished through PFCV. 
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in the PFC-filled lung with associated improvement in 
compliance, improvement in ventilation/perfusion 
matching, and reduction in ventilator airway pressure 
requirements.6-9 
Although the goal of PFCV is to provide .gas 
exchange, few studies have actually measured VO-, 
and VC02 during liquid ventilation.xJO.l’ Those that 
have evaIuated gas exchange during PFCV indicate 
that there is a reduction in the metabolic rate, the 
etiology of which remains unclear. In these studies, 
VOz and/or VCOz during gas and liquid ventilation 
were compared in different animals, under different 
conditions, or by methods with potential for signifi- 
cant measurement inaccuracy. The purpose of this 
study, therefore, is to relate gas exchange in compari- 
son during PFCV and gas ventilation (GV) in the 
same animals under the same conditions by an 
indirect, calorimetric. technique which allows accu- 
rate measurement of VO? and VCO1.“J” 
MATERIALS AND METHODS 
Ten healthy cats weighing 2.6 to 3.0 kg were anesthetized with 
pentobarbital, 25 mgikg. A midline neck incision was performed 
and the trachea as well as the right carotid artery and internal 
jugular vein were isolated. A tracheostomy tube was advanced into 
the trachea to a point above the carina and anchored in place. A jet 
ventilation endotracheal tube (Mallinckrodt, Inc, Argyle, NY) was 
utilized in order to allow measurement of carinal airway pressure. 
An IS-gauge catheter was placed in the carotid artery and a 4F 
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P ULMONARY gas exchange utilizing perfluoro- carbon liquid ventilation (PFCV) has been inves- 
tigated over the past 25 years.‘v4 Efficacy of gas 
exchange in normal animals has been established.5 In 
addition, numerous studies in newborn premature 
animals have demonstrated efficacy in providing re- 
duction of surface tension at the air-liquid interface 
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Spirometer 
Fig 1. A flow-limited, time-cycled device that provides ventilation 
while simultaneously measuring VO, and VCOz during GV. The con- 
trol box allows variation in the frequency and duration of pinch valve 
closure. This, along with variation in the gas flow rate, establishes the 
respiratory rate and TV. 
venous Oximetrix catheter (Oximetrix, Inc, Mountain View, CA) 
was advanced into the right atrium via the right internal jugular 
vein and anchored in place. Mechanical ventilation was instituted 
and pancuronium bromide, 0.1 mgikg, was administered intrave- 
nously at this point and hourly thereafter. Subsequent anesthesia 
was administered in the form of pentobarbital (10 mg/kg/h) 
intravenous infusion in 5% dextrose/Ringer’s lactate solution at a 
maintenance rate of 4 ml/kg/h. 
Measurement of ?Oz and IkO, 
A previously described device was adapted as a flow-limited, 
time cycled ventilator which allowed measurement of VOz and 
VCOz during gas ventilation (Fig 1).r3 This device consists of a 
Cobe occlusive roller pump (Cobe Cardiovascular, Inc, Arvada, 
CO), which induces continuous gas flow at a prescribed rate 
through a closed circuit. The roller pump, the endotracheal tube, 
and a pinch valve are connected in series. A controller box allows 
alteration in inspiratory (IT) and expiratory time (ET) through 
variation of the duration of pinch valve closure. Tidal volume (TV), 
therefore, is dependent on gas flow rate (GFR) and inspiratory 
time. The appropriate gas flow rate for each desired number of 
breaths per minute, inspiratory and expiratory times, and desired 
tidal volume may be calculated using the equation: 
GFR = BPM * (IT + ET)/IT * Desired TV 
Additional components in the closed circuit included a mixing 
chamber and an HP-47210A (Hewlett-Packard, Inc, Waltham, 
MA) or a Novametrix 1260 (Novametrix Medical Systems, Inc, 
Wallingford, CT) capnometer. COz in the circuit was measured via 
the capnometer and then deleted via a CO2 scrubber. 
Measured COz beyond the COz scrubber was documented to be 
less than 0.4 mm Hg during each experiment. The coefficient of 
variation for VCOz measurement utilizing this device was docu- 
mented to be 0.7 ? 0.1.i4 The pump flow rate was calibrated and 
the pressurized closed-circuit tested for leaks at the beginning of 
each study. The barometric pressure was ascertained daily. Stabil- 
ity of the PaCOz at 25 mm Hg between individual VCO? 
measurements was documented. VCOz was calculated based on 
the following equation: 
VCOz (mL/kg/min) = Circuit PC02 (mm Hg) x 
pump flow rate (mL/min)/barometric pressure (mm Hg)/ 
weight of animal (kg) 
Oxygen consumption was evaluated by measurement of volume 
loss from a spirometer in the closed circuit. Since carbon dioxide is 
deleted from the circuit by the CO? scrubber, volume loss in the 
leak-free circuit is only secondary to oxygen consumption. A 
linear-variable differential transformer (LVDT) was adapted to a 
1-L spirometer (Collins, Inc, Braintree, MA), which was used to 
continuously measure oxygen consumption during each period of 
the study. Calibration of the LVDT was performed utilizing a 
secondary spirometer, which demonstrated a conversion of 5.8 mL 
of oxygen consumed per milivolt change in the LVDT. The 
coefficient of variation for VOz measurement utilizing this device 
was 0.4 + 0.1.i4 
A correction factor (CFo) for VOz and VCOz at standard 
temperature and pressure dry (STPD) was applied to all data 
obtained during gas ventilation and was derived from the following 
formula: 
CFo = [273”K/(273” + T)] + [(Atm - PHZO)/Atm] 
where T = the room temperature for VOs measurements and the 
circuit temperature at the capnometer site for VCOz evaluation, 
Atm = atmospheric pressure, and PHzO = water vapor pressure. 
VOs and VCOl measurements during liquid ventilation were 
assessed utilizing a similar apparatus as seen in Fig 2. The pinch 
valve and endotracheal tube are deleted and replaced by the 4.5 m* 
membrane lung (Avecor, Minneapolis, MN) in the closed circuit. 
The roller pump provides a continuous sweep flow through the 
membrane lung as gas exchange occurs between the PFC and the 
closed circuit across the silicone membrane. VOz and VCO, 
measurements were evaluated by similar capnometric and closed- 
circuit, volumetric techniques as described above. However, a 
correction factor (CF& incorporating a factor for the effect of 
liquid vapor pressure (Pprc) during PFCV upon gas exchange 
measurements, was applied to VOz and VCOz measurements: 
CFt_ = [273”K/(273” + T)] + (Atm - PHZO - P,,)/Atm 
Gas Ventilation 
GV was performed utilizing the ventilator depicted in Fig 1. Use 
of this ventilator allowed assessment of VOz and VCO z during 
GV. The ventilator settings included IT = 1 second, ET = 2 
seconds, TV = 15 ml/kg/breath, rate of 20 breaths/min, and 
circuit FiO2 = 1 .O. 
Liquid Ventilation 
A flow-limited, time-cycled perfluorocarbon liquid ventilator 
was developed and used as seen in Fig 3. This ventilator consists of 
an adaptation of an extracorporeal life support circuit. The 
inspiratory and expiratory limbs are “Y’d” at the endotracheal 
Spirometer 
Fig 2. Incorporation of the membrane lung of the liquid ventilator 
into the closed-circuit calorimeter described in Fig 1 allows continu- 
ous measurement of GO, and \jCO, during PFCV. The roller pump 
serves to provide a continuous sweep flow of ventilating gas through 
the membrane lung. 
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PaCOz at onset of GV. Anesthesia was administered by continuous 
infusion of pentobarbital, 10 mgikg, throughout each study. 
Arterial blood gas data were assessed utilizing an ABL 30 Blood 
Gas Analyzer (Radiometer A/S, Copenhagen, Denmark). Blood 




Fig 3. A flow-limited, time-cycled device for liquid ventilation. The 
control box allows variation in IT and ET. During inspiration, the pinch 
valve is occluded and the pump functional such that a tidal volume is 
generated. During expiration, pump function is discontinued which 
occludes the inspiratory limb. Simultaneously, the pinch valve re- 
leases, which allows drainage of PFC into the reservoir. 
GO? and GCOz data collected during each of the lo-minute 
periods were averaged and ?SD determined for GV and PFCV for 
all animals. Arterial blood gas data collected from all animals after 
1 houf of either GV or PFCV were averaged and +SD determined. 
The VCOJVO2 ratio (RQ) was calculated, averaged, and *SD 
determined for GV and PFCV. The paired Student’s t test was 
applied for statistical comparison of data. 
Approval for this study was obtained from the committee on 
university laboratory animal medicine at the University of Michi- 
gan Medical Center and all animal care guidelines followed. 
Animals were euthanized at completion of the study. 
RESULTS 
tube. A pinch valve is present on the expiratory limb followed in 
series by a reservoir, a roller pump, a membrane lung, and a heat 
exchanger. A controller box induces pinch valve closure simulta- 
neously with onset of roller pump function during inspiration. This 
provides occlusion of the expiratory limb during inspiration as 
perfluorocarbon is perfused through the membrane lung and heat 
exchanger and a pulmonary tidal volume is produced. During 
expiration, roller pump activity is discontinued which provides 
occlusion of the inspiratory limb as the pinch valve opens allowing 
drainage of perfluorocarbon from the lungs into the reservoir. 
Initial ventilator settings included an IT of 4 seconds, an ET of 8 
seconds, a rate of 5 breathsimin, a TV of 15 to 20 ml/kg/breath, 
and a membrane lung sweep flow of 2 Limin of oxygen with an 
FiOl = 1.0. The partial pressure of oxygen in the PFC exiting the 
membrane lung (PiOlcprc,) was 380 -+ 102 mm Hg. 
As seen in Fig 4, there was no change in VO?, 
$.C02, or RQ during PFCV when compared to GV 
(VOz: GV = 5.7 2 0.3 mL/kg/min, PFCV = 5.6 ? 0.5 
mL/kg/min [P = NS]; VCO?: GV = 4.9 ? I .l 
mL/kg/min, PFCV = 4.8 * 0.9 mL/kg/min [I’ = NS]; 
RQ: GV = 0.85 2 0.21, PFCV = 0.86 ? 0.21 [P = 
NW. 
Animals were hyperoxygenated and hyperventilated prior to 
institution of liquid ventilation. Warmed, oxygenated PFC (Rimar- 
101. density 1.76 g/mL, Miteni SPA, Milano, Italy) 35 mL/kg was 
then instilled into the endotracheal tube (En) and the lungs 
debubbled. The E’IT was then attached to the liquid ventilator and 
PFCV performed. After liquid ventilation was instituted the 
membrane lung was incorporated into the device used for measure- 
ment of 0: consumption and CO1 production as described above 
(Fig 2). This allowed measurement of qOZ and CC02 during liquid 
ventilation. 
Arterial blood gas data (Fig 5) after 1 hour of GV 
or liquid ventilation demonstrated that the PaOz was 
higher during GV than during PFCV (PaOz: 
GV = 335 + 70 mm Hg, PFCV = 267 % 83 mm Hg 
[P = .04]). This is expected because of the relative 
reduction in the inspiratory partial pressure of oxygen 
in PFC [PiO,,,,,] during liquid ventilation. There was 
no significant change in the PaCO? (PaC02: GV = 
37.3 2 2.2 mm Hg, PFCV = 40.4 + 5.3 mm Hg [P = 
NS]) or the pH (pH: GV = 7.34 + 0.04, PFCV = 
7.35 + 0.06 [P = NS] [Fig 61). 
Measurement of Gas Exchange 
Once stable after performance of tracheostomy and line place- 
ment, the animal was placed on the gas ventilator described 
previously. GO? was then assessed over three consecutive lo- 
minute periods. Capnometric data were collected at the end of 
each of the three lo-minute periods. Liquid ventilation was then 
instituted as described above. Once stable on the liquid ventilator, 
the membrane lung was incorporated into the gas exchange 
measurement device. VOz and VCO2 data were then collected, as 
during GV, over three consecutive lo-minute periods. 
Pancuronium bromide, 0.1 mgikg, was administered immedi- 
ately prior to each series of gas exchange measurements during GV 
and liquid ventilation in order to provide pharmacological paraly- 
sis. Rectal temperature was maintained at 37S”C ? O.S’C at all 
times. The PaC02 was maintained at ?lO mm Hg from the original 
GAS VENTILATION PFC VENTILATION 
Fig 4. Oxygen consumption (GO, [MI), carbon dioxide production 
(\iCO, [O]), and the icCO,l\jO, ratio (RQ [O]) during GV and PFCV. 
0 
GAS VENTILATION PFC VENTILATION 
Fig 5. PaOp (B) and PaCO, (0) during GV and PFCV. l P < .05. 
There was no significant change in heart rate (HR) 
or mean systemic blood pressure (MAP) when GV 
and PFCV were compared (MAP: GV = 102 ? 20 
mm Hg, PFCV = 101 ? 14 mm Hg [P = NS]); HR: 
GV = 129 ? 21 beats/min, PFCV = 147 -+ 29 beats/ 
min [P = NS]). 
DISCUSSION 
This study documents that oxygen consumption 
and carbon dioxide production remain unchanged 
during liquid ventilation when related in comparison 
to that during GV. In addition, provision of adequate 
gas exchange utilizing PFCV in normal animals is 
demonstrated. 
The concept of liquid ventilation extends back to 
the early 1920s when the efficacy of saline as a means 
of altering the physiologic effects of the pulmonary 
gas-liquid interface was investigated.5 However, be- 
cause of the limited solubility of oxygen in saline 
(approximately 2 mL OJdL at PO1 = 700 mm Hg), 
adequate oxygenation could not be provided during 
GAS VENTILATION PFC VENTILATION 
Fig 6. pH during GV and PFCV. 
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saline liquid ventilation except under hyperbaric 
conditions.i5 Interest in the pulmonary apphcations 
of perfluorocarbon liquids, which incorporated prop- 
erties of low surface tension and high oxygen solubil- 
ity, began in 1966.’ At that time, the ability of the 
perfluourocarbon FX-80 to provide adequate gas 
exchange in the spontaneously breathing mouse and 
cat was demonstrated. Since then, a variety of perflu- 
orocarbons have been developed and used, with the 
most recent generation incorporating and enhancing 
such desirable properties as low surface tension, high 
gas solubility, low viscosity to decrease airway resis- 
tance, and relatively high vapor pressure so that the 
perfluorocarbon might evaporate from the airways 
after conversion from liquid to gas ventilation.16 
Subsequent studies have demonstrated improved sur- 
vival, enhanced gas exchange, and increased compli- 
ance in premature newborn animals, full-term lambs 
with meconium aspiration, and in animals with exper- 
imentally induced lung injury.sJ7J8 In addition, the 
first human trials of liquid ventilation in three neo- 
nates have demonstrated feasibility of gas exchange 
utilizing liquid ventilation.r9 
Although the efficacy of gas exchange during liquid 
ventilation has been assessed in numerous studies, 
measurement of VOZ and VC02 has rarely been 
evaluated. Among the studies that have investigated 
gas exchange during perfluorocarbon ventilation in- 
clude those by Sivieri et al’” in 1981 and Harris et al” 
in 1983. In the former, VO? in spontaneously gas- 
breathing animals was compared to that during liquid 
ventilation as measured by a spirometric, volume-loss 
technique similar to the method utilized in this study. 
V02 was found to decrease 18.6% after initiation of 
liquid ventilation. In the second study, Harris et al 
evaluated VOZ and VC02 in animals undergoing 
liquid ventilation by measuring the oxygen tension in 
inspired (P,O,) and expired (PE02) PFC and the 
carbon dioxide tension in inspired (PIC02) and ex- 
pired (PECOZ) PFC and calculating gas exchange 
based on the following equations: 
Voz = v, (Pi02 - (PEOZ) * mo, 
VCOZ = VE (P&O2 - P,COJ * aCOz 
where aOz and aCOz are the solubility coefficients 
for oxygen and carbon dioxide, respectively, in PFC 
and VE is the minute volume ventilation with PFC. 
The derived values of VOZ and VC02 were then 
compared to values obtained in similar fashion from 
another group of animals during GV. VO? and VCOZ 
were reduced in this study after application of liquid 
ventilation by 42% and 35%, respectively. Therefore, 
in both of these studies, gas exchange appeared to be 
reduced during liquid ventilation, although the under- 
VO? AND VCOl DURING LIQUID VENTILATION 
lying physiology accounting for this finding remained 
unclear. 
In the current study, gas exchange during liquid 
ventilation remained unchanged in comparison to 
that noted during GV. We believe that our study 
differ! from those of others for the following reasons: 
1. VO? and VCO, were evaluated by methods 
which allowed accurate measurement of gas 
exchange. In the study by Harris et al, evaluation 
of gas exchange was based on measurements of 
oxygen and carbon dioxide tensions in inspired 
and expired perfluorocarbon in order to calcu- 
late GO1 and cCO1. The authors, in discussing 
their results, note that the calculations for VOZ 
and QCO, are dependent on solubility coeffi- 
cients for these gases in PFC and that a variety 
of differing solubility coefficients have been 
determined, which may induce up to a 20% to 
30% variation depending on the coefficient 
used. In contrast, the present study used an 
indirect, closed-circuit calorimetric technique 
that allowed accurate measurement of VOZ and 
VCO? without need for application of a gas 
solubility coefficient. 
2. in the study by Sivieri et al, animals were 
spontaneously respiring during gas breathing, 
but were pharmacologically paralyzed and venti- 
lated during liquid breathing. In normal ani- 
mals, the resting energy expenditure from breath- 
ing is approximately 1% to 5% of overall oxygen 
consumption and is even greater during periods 
of hyperventilation.‘0 In addition, pharmacolog- 
ical paralysis may result in an 11% reduction in 
VO’.” Mechanical ventilation and pharmacolog- 
ical paralysis, therefore, could account for the 
reduction in oxygen consumption noted in the 
study by Sivieri et al. In contrast, in the present 
study, animals were pharmacologically para- 
lyzed and mechanically ventilated when gas 
exchange measurements were performed during 
both GV and PFCV. 
The accuracy of the closed-circuit, indirect calori- 
metric technique for evaluating VOz and VCO? has 
been previously documented.12J” The efficacy of a 
modification of this technique for the measurement 
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of gas exchange during liquid ventilation has been 
demonstrated in this study. A number of factors, 
however,.may affect the metabolic rate or the measure- 
ment of V02 and VC02. For instance: 
Gas exchange could potentially have been al- 
tered because of variation in the PaCOz and pH. 
The metabolic rate has been shown to increase 
with a rising pH and diminishing PaCO>. This 
change in VOz has been demonstrated to in- 
crease approximately 7% for each 10 mm Hg 
decrease in PaCO 2.22 PaCO? values during this 
study were, therefore, maintained at -+lO mm 
Hg from the initial PaCO?. 
The metabolic rate may be altered with temper- 
ature, level of sedation, and paralysis. There- 
fore, all of these were carefully controlled 
throughout this s.fudy. 
Stability of the VCO? and PaGO? are required 
fpr accurate assessment of VCO?. However, 
VCO,, as measured by the method used in this 
study, would not have been affected by the 
absolute PaCO? value as long as that value was 
relatively stable. A stable PaCO, (k5 mm Hg 
between gas exchange measurements) was en- 
sured during all measurements of VCO?. There- 
fore, any differences in PaCO? seen between gas 
and liquid ventilation would not have affected 
the measured kO1. 
Excellent gas exchange capabilities were docu- 
mented during perfluorocarbon ventilation. The slight, 
but significant, reduction in the PaOz during PFCV 
when compared to GV is expected because of the 
relative reduction in inspiratory partial pressure of 
oxygen in PFC (PiO,(,,,, ) during liquid ventilation 
(Pi02(ptcc) = 380 k 102 mm Hg) in comparison to the 
PiO. of the closed circuit during GV (FiOz = 1.0, 
PiO, = approximately 700 mm Hg). If adequate time 
is allowed, the partial pressure of oxygen in PFC will 
equilibrate with the partial pressure of oxygen in the 
gas to which the PFC is exposed. Therefore, this 
reduction in PiOZ(pfcj and Pa03 is a reflection of minor 
limitations in the liquid ventilator device utilized, 
rather than being inherent to the liquid ventilation 
technique itself. 
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Discussion 
F.J. Rescorla (Indianapolis, IN): Liquid ventilation 
with the use of perfluorcarbons has been studied for 
the past 25 years. Recent advances in the develop- 
ment of these compounds takes advantage of the low 
surface tension, high gas solubility, and low viscosity 
allowing delivery of oxygen and elimination of CO? in 
a low-pressure system. Animal models using liquid 
ventilation to treat meconium aspiration and other 
experimental lung injuries have noted increased com- 
pliance, enhanced gas exchange, and improved sur- 
vival. Liquid ventilation has also been shown to 
extend the limits of viability of immature lambs 
presumably by eliminating the dependency on surfac- 
tant. The recent initial human studies have demon- 
strated the feasibility of the model in premature 
babies. However, the very viable nature of the initial 
subjects that being a pH of 6.77 to 7.22 and short term 
survival and 19 hours at the maximum prevents 
determination of therapeutic benefits. Dr Hirsch1 and 
his colleagues have made a significant contribution to 
the field of liquid ventilation. They have demon- 
strated the efficacy of measuring oxygen consumption 
and carbon dioxide production during liquid ventila- 
tion using an indirect calorometic technique. They 
have shown that oxygen consumption and CO? produc- 
tion do not change during liquid ventilation and that 
excellent gas exchange can be accomplished due to 
fluorocarbon ventilation. My questions are as follows. 
In your model, the inspiratory partial pressure of 
oxygen in PFCV was 380 & 102 mm Hg compared to 
approximately 700 mm Hg in the GV system. I 
understand from the manuscript that this is limited by 
your present system. Therefore, do you have plans to 
change your system to allow a higher partial pressure 
of oxygen in perfluorocarbon? Second, what do you 
foresee as the clinical application of this therapy? 
Will it be limited initially to prematures as in the 
initial clinical trial? Will it increase the viability of the 
fetus to a lower gestational age? Could this modality 
be used in the older infants and children with acute 
insults such as inhalation injuries and severe respira- 
tory distress of other causes? And, finally, how can 
you avoid the situation experienced by other new 
therapies in which only the sickest and probably 
unsalvageable children are offered the new therapy. 
This appears to be the situation in the initial clinical 
trial. What do you foresee as the future for this 
modality? 
W.J. Chwals (Winston-Salem, NC): Hirschl, in as 
much as the difference between ventilation conven- 
tionally and PFCV may be due to a difference in 
muscle tone in terms of energy expenditure, is the fact 
that your model involved paralysis not likely to reduce 
any differences which may be seen in conventional 
ventilation versus the PFCV model? In previous 
studies, the ventilatory mode when conventional ven- 
tilation was used is seldom complemented by paraly- 
sis. 
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R.B. Hinchl (response): Yes, the Pi02, the inspira- 
tory partial pressure of oxygen, was decreased with 
the liquid ventilator. We have already made changes 
in this system. These include allowing continuous 
flow of perfluorocarbon through the membrane lung 
which will alter the Pi02 of the perfluorocarbon and 
which should improve the arterial oxygenation. With 
regard to possible clinical applications, I think that 
there is potential for wide-spread use not just in 
premature newborns, but in other neonates, children, 
and adults. The key benefit of PFCV is the elimina- 
tion of the alveolar air-fluid interface with a reduction 
in alveolar surface tension. That’s true especially with 
surfactant deficiency which is often present in the 
setting of respiratory failure. In addition, in situations 
where the alveoli are filled with fluid, perfluorocar- 
bons may replace that fluid, allowing gas exchange to 
take place. These advantages of PFCV in the setting 
of respiratory failure will likely make this new modal- 
ity applicable to all age groups. With regard to fetal 
application, there is a lot of speculation. It goes all the 
way to the point where you could imagine a prema- 
ture baby submerged in the perfluorocarbon with gas 
exchange, in some fashion, being accomplished via 
the perfluorocarbon. However, there is a point where 
the lung is not adequately developed and ventilation 
with perfluorocarbons would not be applicable below 
that level. PFCV is at a point where evaluation in 
nonmoribund newborns is required. Our plan is to try 
to implement and explore this new modality on 
ECMO because it provides a safe setting for doing so. 
In addition, we are performing studies right now to 
evaluate whether PFCV will actually improve gas 
exchange and pulmonary function in newborns on 
ECMO. The pulmonary opacification that we observe 
after onset of bypass may be due to atelectasis and 
may actually be improved by PFCV. In addition, 
lavage with perfluorocarbons may allow removal of 
meconium from the lungs in the setting of the 
meconium aspiration syndrome. This has been shown 
to be true in animal models, with associated improve- 
ment in pulmonary function. With regard to the use 
of paralysis in this study, a previous study was done in 
which spontaneously breathing animals were com- 
pared to mechanically liquid ventilated animals. As 
would be expected, an increase in oxygen consump- 
tion in the spontaneously breathing animals was 
noted. We chose, therefore, to investigate whether 
there was a primary increase in baseline oxygen 
consumption and carbon dioxide production from the 
modality itself. I think that the best way to do that was 
to maintain control of all factors of oxygen consump- 
tion, which included the use of paralysis for both 
groups. 
